PHAT Phathom Pharmaceuticals, Inc.

NASDAQ
$7.30

Phathom Pharmaceuticals, Inc. (PHAT) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.01 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.0% since its last earnings release on July 30, 2026.

Phathom Pharmaceuticals Beat Consensus Estimates, Lowers Guidance
Thursday, July 30, 2026 · 6:59 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.01)
Rev est $86.83M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.65

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.